Revenue (Quarterly)

Revenue: The sum of all revenue fields included for a company's operating activities.

Elite Pharmaceuticals Inc. (ELTP) had Revenue of $31.59M for the most recently reported fiscal quarter, ending 2025-12-31.

Quarterly Annual

Figures for fiscal quarter ending 2025-12-31

Income Statement Financials
Revenue	$31.59M
Net Income	$18.59M
Cost of Goods Sold	$18.64M
Gross Profit	$12.95M
Operating Expenses	$22.58M
Operating Income	$9.01M
Non-Operating Income/Expense	$11.82M
Pre-Tax Income	$20.83M
Normalized Pre-Tax Income	$20.83M
Income after Taxes	$18.59M
Income from Continuous Operations	$18.59M
Consolidated Net Income/Loss	$18.59M
Normalized Income after Taxes	$18.59M
EBIT	$9.01M
EBITDA	$9.52M
Weighted-Average Shares Outstanding (Basic)	1.07B
Weighted-Average Shares Outstanding (Diluted)	1.14B
Earnings per Share (EPS) (Basic)	$0.02
Earnings per Share (EPS) (Diluted)	$0.01
Balance Sheet Financials
Current Assets	$96.79M
Property, Plant, and Equipment	$10.04M
Long-Term Assets	$29.62M
Total Assets	$126.41M
Current Liabilities	$13.19M
Long-Term Debt	$3.78M
Long-Term Liabilities	$32.91M
Total Liabilities	$46.10M
Common Equity	$80.31M
Tangible Shareholders Equity	$74.68M
Shareholders Equity	$80.31M
Common Shares Outstanding	1.07B
Cash Flow Statement Financials
Cash Flow from Operating Activities	$14.60M
Cash Flow from Investing Activities	$-0.53M
Cash Flow from Financial Activities	$-4.28M
Beginning Cash	$11.77M
End Cash	$21.56M
Increase/Decrease in Cash	$9.79M
Stock-Based Compensation	$0.15M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	7.34
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.04
Debt to Equity Ratio	0.05
Gross Margin	41.01%
Operating Margin	28.53%
EBIT Margin	28.53%
EBITDA Margin	--
Pre-Tax Profit Margin	65.95%
Profit Margin	58.86%
Free Cash Flow	$14.07M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.25
Inventory Turnover	0.74
Receiveable Turnover	0.65
Days Sales in Receivables	138.26
Return on Equity	23.15%
Return on Tangible Equity	24.90%
Return on Assets	14.71%
Return on Investments	22.11%
Book Value Per Share	$0.07
Free Cash Flow per Share	$0.01
Operating Cash Flow per Share	$0.01

Data from Zacks Investment Research, Inc.